----item----
version: 1
id: {22CC1896-3C40-4791-97D9-E48C6E7C8644}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/10/14/Mina Therapeutics Appoints Chief Scientific Officer
parent: {604E8046-5BA9-4567-9E2A-9612EB50B405}
name: Mina Therapeutics Appoints Chief Scientific Officer
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 0ad4ba14-5006-4499-bc8a-33fe184a2181

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 52

Mina Therapeutics Appoints Chief Scientific Officer 
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 51

Mina Therapeutics Appoints Chief Scientific Officer
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 346

<p>Mina Therapeutics has appointed David Blakey chief scientific officer. Blakey joins the company from AstraZeneca where he held various roles in research and development over 28 years. Most recently, Blakey was chief scientific in oncology and before this he led the company's first collaboration in therapeutic antibodies with Abgenix. </p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 343

<p>Mina Therapeutics has appointed David Blakey chief scientific officer. Blakey joins the company from AstraZeneca where he held various roles in research and development over 28 years. Most recently, Blakey was chief scientific in oncology and before this he led the company's first collaboration in therapeutic antibodies with Abgenix. </p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 51

Mina Therapeutics Appoints Chief Scientific Officer
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20151014T180003
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20151014T180003
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20151014T180003
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC030053
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 52

Mina Therapeutics Appoints Chief Scientific Officer 
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{202BB75B-8718-40FC-96EC-851DBBB43362}
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

360960
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042506Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

0ad4ba14-5006-4499-bc8a-33fe184a2181
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042506Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
